In summary, our study elucidates the synergism between venetoclax and ATO in promoting LSC apoptosis by inhibiting AKT and ERK, leading to GSK-3β activation and Mcl-1 destabilisation, which will support future preclinical and clinical trials evaluating the suitability of this combination for treating AML. Here, MCL1 is linked to acute myeloid leukemia.